Clinical Trial Update: 3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA [Phase 1]

View source ↗

Summary

The Phase 1 trial evaluating third-generation GD2-targeted CAR-NKT cell therapy for neuroblastoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• GD2 CAR-NKT cell therapy (3rd generation GD2-specific chimeric antigen receptor-transduced autologous natural killer T cell therapy)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Neuroblastoma | Phase 1 | Status: WITHDRAWN